CONMED (CNMD) – Investment Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for CONMED (NYSE: CNMD):

• 2/6/2025 – CONMED was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $70.00 price target on the stock, down previously from $85.00.
• 2/6/2025 – CONMED had its price target lowered by analysts at Wells Fargo & Company from $74.00 to $70.00. They now have an “equal weight” rating on the stock.
• 2/6/2025 – CONMED had its price target raised by analysts at Stifel Nicolaus from $72.00 to $75.00. They now have a “buy” rating on the stock.
• 2/6/2025 – CONMED had its price target lowered by analysts at Needham & Company LLC from $97.00 to $91.00. They now have a “buy” rating on the stock.

CONMED Stock Performance

Shares of CONMED stock opened at $65.04 on Wednesday. The firm’s fifty day simple moving average is $70.01 and its 200-day simple moving average is $70.07. CONMED Co. has a 12 month low of $61.05 and a 12 month high of $88.60. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of 15.34, a PEG ratio of 1.05 and a beta of 1.46. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.27 and a quick ratio of 1.06.

CONMED (NYSE:CNMD) last released its quarterly earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.14. CONMED had a return on equity of 14.60% and a net margin of 10.13%. As a group, equities analysts forecast that CONMED Co. will post 4.35 earnings per share for the current year.

CONMED Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 3rd. Investors of record on Friday, December 20th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, December 20th. This represents a $0.80 annualized dividend and a yield of 1.23%. CONMED’s dividend payout ratio is currently 18.87%.

Hedge Funds Weigh In On CONMED

A number of large investors have recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in CONMED by 93.6% during the fourth quarter. GAMMA Investing LLC now owns 726 shares of the company’s stock worth $50,000 after buying an additional 351 shares in the last quarter. CWM LLC lifted its position in shares of CONMED by 36.1% during the 3rd quarter. CWM LLC now owns 1,251 shares of the company’s stock valued at $90,000 after acquiring an additional 332 shares during the period. Pacer Advisors Inc. boosted its stake in shares of CONMED by 41.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,656 shares of the company’s stock worth $113,000 after acquiring an additional 485 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of CONMED by 19.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,962 shares of the company’s stock worth $136,000 after acquiring an additional 322 shares during the period. Finally, nVerses Capital LLC increased its stake in CONMED by 566.7% in the 3rd quarter. nVerses Capital LLC now owns 2,000 shares of the company’s stock valued at $144,000 after purchasing an additional 1,700 shares in the last quarter.

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.